KOSDAQBiotech & Pharma115450

HLB Therapeutics

₩1,317▼ 5.73%2026-11-18 close
Market Cap
₩124.7B
Turnover
₩2.3B
Volume
1.7M
Shares out.
94.7M
PER
—
PBR
1.5×
EPS
-₩213
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Phase 3 readout and FDA review set the next test

HLB Therapeutics pairs a cold chain distribution business with a drug pipeline, and its next checkpoints are the RGN-259 global Phase 3 topline readout, expected in November 2026, and the FDA target date for the rivoceranib-camrelizumab combination, April 9, 2027.

  1. 1

    Revenue reached KRW 69.6 billion in 2025, up 26.6% year on year, while the operating loss narrowed to KRW 3.53 billion.

  2. 2

    Attributable net losses have continued for three straight quarters from Q1 2026 through Q3 2026, totaling KRW 18.9 billion over the last four quarters.

  3. 3

    Q3 2026 revenue rose 28.0% year on year to KRW 20.6 billion, yet the operating loss of KRW 4.11 billion and the attributable net loss of KRW 6.37 billion persisted.

  4. 4

    The RGN-259 global Phase 3 topline is planned for release in November 2026, and the FDA has set April 9, 2027 as the review target date for the rivoceranib-camrelizumab combination.

  5. 5

    Public vaccine distribution volumes fell in the first half of 2026, and consolidated revenue of KRW 25.6 billion was down 16.6% year on year, per the 2026 half-year report.

02

Business structure

HLB Therapeutics runs two business lines: drug development and cold chain storage and transport for vaccines and biologics.

In drug development, its U.S. subsidiary is running the global Phase 3 trial (SEER-2) of RGN-259 for neurotrophic keratitis, while its U.S. subsidiary Elevar Therapeutics is pursuing U.S. approval for rivoceranib combined with camrelizumab, the PD-1 antibody from China's Hengrui Pharma, as a first-line liver cancer treatment.

RGN-259 is designed for room temperature storage and dosing five times a day for four weeks, compared with refrigerated storage and six daily doses for eight weeks for Oxervate, which the group cites as the only competing product.

The group also points to FDA orphan drug designation for RGN-259 as part of the program's rationale.

The cold chain unit handles storage and transport of vaccines for the national immunization program and other biologics, and its revenue depends on distribution volumes and public procurement schedules rather than clinical outcomes.

In July 2026 the company said it had obtained an international standard certification for its cold chain quality and environmental management system.

In the same month it disclosed a shareholder meeting on a plan to spin off the electronics unit, which makes boiler motors and pumps, into a newly formed unlisted company. The company said it would still run drug development and cold chain as its two pillars after the split. Because the pipeline is still before approval, current revenue comes mainly from cold chain distribution.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.1B-₩5.4B−33.5%
2025Q4₩22.8B₩4.1B18.0%
2026Q1₩13B-₩3.2B−24.8%
2026Q2₩12.6B-₩4.7B−37.7%
2026Q3₩20.6B-₩4.1B−20.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48.1B-₩7.9B-₩11.4B−16.4%−9.7%46.5%
2023₩53.7B-₩8.7B-₩2.3B−16.2%−1.4%17.1%
2024₩54.9B-₩7.6B-₩22.8B−13.9%−14.5%20.9%
2025₩69.6B-₩3.5B-₩9.2B−5.1%−6.1%31.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue was KRW 48.1 billion in 2022, KRW 53.7 billion in 2023, KRW 54.9 billion in 2024 and KRW 69.6 billion in 2025, rising for three straight years from 2023 through 2025, with 2025 up 26.6%.

The operating loss was KRW 7.88 billion in 2022, KRW 8.7 billion in 2023, KRW 7.62 billion in 2024 and KRW 3.53 billion in 2025, a loss in each of the four years, and the operating margin improved from -16.4% in 2022 to -5.1% in 2025.

The attributable net loss was KRW 11.4 billion in 2022, KRW 2.3 billion in 2023, KRW 22.8 billion in 2024 and KRW 9.23 billion in 2025, while the net loss including non-controlling interests was KRW 12.1 billion, KRW 3.08 billion, KRW 23.5 billion and KRW 9.67 billion for the same years.

The debt-to-equity ratio was 46.5% in 2022, 17.1% in 2023, 20.9% in 2024 and 31.5% in 2025, and at the end of 2025 total equity was KRW 173.9 billion, of which equity attributable to owners of the parent was KRW 150.3 billion, with total liabilities of KRW 54.8 billion.

Operating cash flow was -KRW 8.81 billion in 2022, KRW 3.33 billion in 2023, KRW 1.29 billion in 2024 and -KRW 8.18 billion in 2025.

On a quarterly basis, revenue was KRW 16.1 billion in Q3 2025 with an operating loss of KRW 5.38 billion, then turned to an operating profit of KRW 4.09 billion in Q4 2025 on revenue of KRW 22.8 billion.

Revenue fell 42.7% quarter on quarter to KRW 13 billion in Q1 2026, with an operating loss of KRW 3.24 billion, and the operating loss widened to KRW 4.73 billion in Q2 2026 on revenue of KRW 12.6 billion.

Q3 2026 revenue was KRW 20.6 billion, up 63.7% quarter on quarter and 28.0% year on year, and the operating loss narrowed to KRW 4.11 billion.

However, the attributable net loss of KRW 6.37 billion in Q3 2026 was larger than the KRW 5.48 billion loss in Q3 2025, so the operating and attributable results moved in different directions.

Per the 2026 half-year report, first-half consolidated revenue of KRW 25.6 billion was down 16.6% year on year, and press coverage attributed the decline to lower public vaccine distribution volumes after a shift in COVID-19 vaccine mix.

05

Industry analysis

Neurotrophic keratitis is a rare eye disease in which damage to the corneal nerves reduces corneal sensation and the cornea's natural healing ability. The group cites Oxervate as the only competing product for this indication and points to FDA orphan drug designation as part of its development rationale.

Commentary also notes that the market is not a blockbuster-scale opportunity.

In first-line liver cancer treatment, the rivoceranib and camrelizumab combination recorded median overall survival of 23.8 months in the global Phase 3 CARES-310 trial, versus 15.2 months for the sorafenib control arm, with a hazard ratio of 0.64.

Before FDA approval, the combination was included as a first-line option for advanced hepatocellular carcinoma in the 2025 BCLC guideline and the ESMO guideline.

FDA review, however, turns on manufacturing and quality requirements as well as clinical efficacy, and the July 2026 complete response letter cited cGMP inspection findings at a Chinese manufacturing facility.

The cold chain market depends on the national immunization program and public procurement, so changes in COVID-19 vaccine mix quickly flow through to distribution volumes and revenue.

Market commentary says the company's value currently reflects mainly its existing cold chain business, with the neurotrophic keratitis pipeline given limited weight. HLB Group, for its part, has said it spreads risk by keeping a separate R&D subsidiary for each therapy under its listed affiliates.

06

Outlook

The nearest checkpoint is the topline result of the RGN-259 global Phase 3 trial (SEER-2). The company said the last patient's final visit was completed in August 2026 and that topline results are planned for release in November 2026.

The rivoceranib and camrelizumab combination was resubmitted on October 9, 2026, and FDA classified it as a Class 2 resubmission with a review target date of April 9, 2027. HLB Group chairman Yang-gon Jin has said a decision could come as early as this year, but the FDA's official target date is April 9, 2027.

The company said it plans to file for RGN-259 approval in Europe after the United States. If approved, the company said it could work with a global pharmaceutical partner and use that partner's local sales organization.

The company had earlier said it expected cold chain revenue to grow 35% a year through 2026, but first-half 2026 revenue fell year on year as public vaccine volumes declined. Public vaccine procurement schedules are therefore a key variable for near-term cold chain revenue.

The spin-off of the non-bio electronics unit was disclosed in July 2026, and how the two-pillar structure appears in reported results will become visible in later filings. The next regular report is the 2026 annual report, which will confirm full-year operating loss and cash flow.

07

Valuation

PER
—
PBR
1.5×
ROE
-13.3%
EPS
-₩213
BPS
₩1,542
Dividend per share
₩0

Because attributable net losses over the last four quarters total KRW 18.9 billion, no earnings-based multiple can be calculated. On a net asset basis, market capitalization sits above the book value of equity attributable to owners of the parent, so the shares trade at a premium to net assets.

The dividend yield is below the industry average. Operating profit and attributable net profit did turn positive in Q4 2025, but attributable net losses have continued through Q1 to Q3 2026, so a sustained earnings recovery has not yet been shown.

Market commentary holds two views: that the company's value currently reflects mainly its existing cold chain business, and that the pipeline could be revalued depending on the RGN-259 Phase 3 result.

Recent disclosures on conversion price adjustments and corrections to convertible bonds mean potential share dilution is also a factor in valuation. Among listed peers, the company's market capitalization is relatively small, so share price moves around trial and approval milestones can be large.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Room for pipeline revaluation if Phase 3 is positive

If the RGN-259 Phase 3 topline is positive, the pipeline could be reflected in a company value now built mainly on cold chain. The company cites room temperature storage and a four-week, five-times-daily regimen as advantages over Oxervate. Orphan drug designation is described as reducing FDA application fees and creating room for higher pricing.

Clinical evidence and re-entry into FDA review for liver cancer

In the CARES-310 Phase 3 trial, the combination reached median overall survival of 23.8 months, versus 15.2 months for the sorafenib arm. The combination was included as a first-line option in the 2025 BCLC and ESMO guidelines. Acceptance of the October 2026 resubmission as a Class 2 application restarted the full FDA review.

Cold chain base and a recent revenue rebound

The cold chain business rests on experience distributing vaccines for the national immunization program. The company obtained an international standard certification for its cold chain quality and environmental management system in July 2026. Q3 2026 revenue of KRW 20.6 billion rose 63.7% quarter on quarter and 28.0% year on year.

09

Bear factors

Continued quarterly losses and wider attributable net loss

Operating losses have continued for three straight quarters from Q1 2026 through Q3 2026. Attributable net losses total KRW 18.9 billion over the last four quarters.

The Q3 2026 operating loss narrowed year on year, but the attributable net loss of KRW 6.37 billion was larger than the KRW 5.48 billion recorded in Q3 2025.

Approval delays linked to manufacturing quality issues

The rivoceranib application received a complete response letter from FDA in July 2026, citing cGMP inspection findings at a Chinese manufacturing facility. Press coverage described the current bid as the fourth U.S. attempt for the liver cancer drug. With the review target set for April 9, 2027, final approval status will not be known before then.

Lower public vaccine volumes and possible dilution from convertible securities

Lower public vaccine distribution volumes in the first half of 2026 reduced consolidated revenue to KRW 25.6 billion, down 16.6% year on year. Operating cash flow was -KRW 8.18 billion in 2025, despite total equity of KRW 173.9 billion at year-end.

Recent conversion price adjustments and corrections to convertible bond disclosures leave the possibility of dilution for existing shareholders.

10

Risk factors

Clinical and regulatory risk

If the main RGN-259 Phase 3 results fall short of expectations, the way the pipeline is valued could change. The rivoceranib and camrelizumab combination must meet manufacturing and quality requirements alongside clinical efficacy, and the decision could slip past the target date. Even with approval, separate procedures for other regions such as Europe remain.

Financial and dilution risk

Operating and attributable net losses have persisted across several quarters, so the need for external funding remains. Continued conversion price adjustments mean existing shareholders could see dilution if the bonds are converted. The debt-to-equity ratio rose to 31.5% in 2025 from 17.1% in 2023.

Business structure and group dependence risk

Cold chain revenue moves sharply with public vaccine procurement schedules and volumes. The spin-off of the non-bio unit changes the business structure, so the post-split reporting mix will need to be watched.

Delays in a parent company's drug approval have previously pushed down shares of related listed companies in the group, so group-wide events can affect the stock.

11

What to watch next

  1. November 2026

    Topline results of the RGN-259 global Phase 3 trial (SEER-2). Whether the primary endpoint is met and whether the convenience claims versus Oxervate are supported by data are the points to check.

  2. Late March 2027

    Filing of the 2026 annual report. Full-year operating loss, attributable net loss and operating cash flow will be disclosed as confirmed figures, which can be compared with the quarterly results.

  3. April 9, 2027

    FDA target action date (PDUFA) for the rivoceranib and camrelizumab combination. This is when the approval decision and the status of manufacturing facility requirements will be settled.

12

Overall view

HLB Therapeutics combines a cold chain distribution business with a drug pipeline. On a disclosed basis, revenue rose 26.6% in 2025 and the operating loss narrowed to KRW 3.53 billion. However, attributable net losses have continued from Q1 through Q3 2026, totaling KRW 18.9 billion over the last four quarters.

Q3 2026 revenue of KRW 20.6 billion was up 28.0% year on year, but the attributable net loss widened. The next pipeline checkpoints are the RGN-259 Phase 3 topline, planned for November 2026, and the FDA target date for the rivoceranib and camrelizumab combination, April 9, 2027.

Supporters point to clinical data, orphan drug designation and guideline inclusion, while skeptics point to continued losses, the complete response letter tied to manufacturing quality, and possible dilution from convertible bonds.

How much of the company's value rests on its existing business versus its pipeline may look different after the Phase 3 result and the FDA decision. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. alphasquare.co.kr
  2. pinpointnews.co.kr
  3. newspim.com
  4. m.news.nate.com
  5. investing.com
  6. job-post.co.kr
  7. news.nate.com
  8. medifonews.com
  9. digitaltoday.co.kr
  10. hlbtherapeutics.co.kr
  11. kdfnews.com
  12. hankyung.com
  13. etoday.co.kr
  14. biospectator.com
  15. dailian.co.kr
  16. insightkorea.co.kr
  17. news.jkn.co.kr
  18. newstown.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis